Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (809)	5/19/2003 5:16:13 PM
From: Madharry	Respond to of 3559

That's nice information but what do they now with that information ? Will the FDA now require a new study? Did the publish somewhere the actual weights and results by trial participant?

To: nigel bates who wrote (809)	5/19/2003 7:56:06 PM
From: Miljenko Zuanic	Respond to of 3559

Nigel, I do not believe that true problem for A is antibody or selection of the correct obesity population, early responders. GNSC, or anyone else can not help them. The problem is in Axokine dose, “1MCG/KG” selected as optimal dose (One big BS) , for something that has short plasma half life and it has to cross BBB, actually diffuse into hypothalamus. Also: “Additional exploratory analyses revealed that patients who appeared to benefit the most from either AXOKINE treatment or a weight reduction program alone were those subjects who lost at least 4 kilograms (8.8 pounds) after 3 months of therapy ("early responders").” I thought that HOT WATER was discovered bazzilians years ago? <g> But, to make think clear, in my view so far Axokine has the best target profile, only one need to find how to dose drug at therapeutic level, not sub-optimal. Miljenko